Ahmed Elkhanany
@elkhanany.bsky.social
Assistant Prof. of Breast Onc at @bcmhouston.bsky.social. BrCA disparity. Dad to 2 boys. Husband. Into R, Philosophy, Violin, Photography, & JRPGs.
Reposted by Ahmed Elkhanany
⏱️ The next cancer cure is on hold.
@NIH grants invest in future science gains that pay back for our citizens at a rate of more than 2:1 in economic activity.
We are losing the battle for discovery.
@NIH grants invest in future science gains that pay back for our citizens at a rate of more than 2:1 in economic activity.
We are losing the battle for discovery.
Trump hits NIH with ‘devastating’ freezes on meetings, travel, communications, and hiring
Researchers facing
www.science.org
January 23, 2025 at 2:29 AM
⏱️ The next cancer cure is on hold.
@NIH grants invest in future science gains that pay back for our citizens at a rate of more than 2:1 in economic activity.
We are losing the battle for discovery.
@NIH grants invest in future science gains that pay back for our citizens at a rate of more than 2:1 in economic activity.
We are losing the battle for discovery.
Reposted by Ahmed Elkhanany
#SABCS24 #bcsm #OncSky #MedSky
Following up with a few resources from FDA-@abreastcancer session today for #breastcancer #advocacy community
Someone asked for email to report misleading drug ads: BadAd@fda.hhs.gov
/1
@oncoalert.bsky.social
Following up with a few resources from FDA-@abreastcancer session today for #breastcancer #advocacy community
Someone asked for email to report misleading drug ads: BadAd@fda.hhs.gov
/1
@oncoalert.bsky.social
a blue speech bubble with the words speak your mind
ALT: a blue speech bubble with the words speak your mind
media.tenor.com
December 13, 2024 at 12:24 AM
#SABCS24 #bcsm #OncSky #MedSky
Following up with a few resources from FDA-@abreastcancer session today for #breastcancer #advocacy community
Someone asked for email to report misleading drug ads: BadAd@fda.hhs.gov
/1
@oncoalert.bsky.social
Following up with a few resources from FDA-@abreastcancer session today for #breastcancer #advocacy community
Someone asked for email to report misleading drug ads: BadAd@fda.hhs.gov
/1
@oncoalert.bsky.social
Reposted by Ahmed Elkhanany
PRACTICE CHANGING findings from PATINA presented by Dr. Metzger from @dfcibreastonc.bsky.social
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies
December 12, 2024 at 5:57 PM
PRACTICE CHANGING findings from PATINA presented by Dr. Metzger from @dfcibreastonc.bsky.social
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies
Hyping for my smart dear friend @yabdoumd.bsky.social from UNC, who is moderating Poster Spotlight Session 9: ctDNA Uses for Minimal Residual Disease Testing, Tumor Evolution, and Novel Technologies. Tomorrow at 7 AM at Stars at Night 3-4
#SABCS2024
#bcsm
@sabcs.bsky.social
#SABCS2024
#bcsm
@sabcs.bsky.social
December 12, 2024 at 6:21 AM
Hyping for my smart dear friend @yabdoumd.bsky.social from UNC, who is moderating Poster Spotlight Session 9: ctDNA Uses for Minimal Residual Disease Testing, Tumor Evolution, and Novel Technologies. Tomorrow at 7 AM at Stars at Night 3-4
#SABCS2024
#bcsm
@sabcs.bsky.social
#SABCS2024
#bcsm
@sabcs.bsky.social
Absolutely important. “Shared” decision requires active effort by oncologists to simplify, relate and iterate findings, while not encumbering patients with nuances.
“Its not shared decision making if we [patients] are not informed” @amybeumer #SABCS24
December 12, 2024 at 2:37 AM
Absolutely important. “Shared” decision requires active effort by oncologists to simplify, relate and iterate findings, while not encumbering patients with nuances.
Another great study run by TBCRC and lead by my dear colleague Dr. Julie Nangia at @bcmhouston.bs. #042 used Ruxolitinib for 10-20 days b4 surgery to inhibit pSTAT5 pathway in premalig AH/CIS (ductal/lobular). 1ry endpoint is apoptosis by Caspase3 drop pending. Congrats
#SABCS24
#bcsm
#SABCS24
#bcsm
December 12, 2024 at 2:09 AM
Sobering data on 7-year IBC outcome from @mdanderson.bsky.social presented by superstar Dr. Azadeh Nasrazadani. 7-year OS % 7, 24, 50, 55 in TNBC, ER+ HER2-, ER- HER2+ and ER+HER2+. CDK4/6i benefit low compared with historic cohorts. @naborala.bsky.social we need better Rx.
#SABCS24
#bcsm
#SABCS24
#bcsm
December 11, 2024 at 11:48 PM
Sobering data on 7-year IBC outcome from @mdanderson.bsky.social presented by superstar Dr. Azadeh Nasrazadani. 7-year OS % 7, 24, 50, 55 in TNBC, ER+ HER2-, ER- HER2+ and ER+HER2+. CDK4/6i benefit low compared with historic cohorts. @naborala.bsky.social we need better Rx.
#SABCS24
#bcsm
#SABCS24
#bcsm
Reposted by Ahmed Elkhanany
“It is impressive that the combination [of imlunestrant and abemaciclib] seems to tower above the rest” — @DrHalBurstein
sharing his self-proclaimed dreaded cross trial comparison (students, biostatisticians: *avert your eyes*) #SABCS24 @oncoalert.bsky.social
sharing his self-proclaimed dreaded cross trial comparison (students, biostatisticians: *avert your eyes*) #SABCS24 @oncoalert.bsky.social
December 11, 2024 at 3:45 PM
“It is impressive that the combination [of imlunestrant and abemaciclib] seems to tower above the rest” — @DrHalBurstein
sharing his self-proclaimed dreaded cross trial comparison (students, biostatisticians: *avert your eyes*) #SABCS24 @oncoalert.bsky.social
sharing his self-proclaimed dreaded cross trial comparison (students, biostatisticians: *avert your eyes*) #SABCS24 @oncoalert.bsky.social
Reposted by Ahmed Elkhanany
#EMBER3
Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut
However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1
* note prior CDK not required
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut
However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1
* note prior CDK not required
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 11, 2024 at 3:27 PM
#EMBER3
Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut
However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1
* note prior CDK not required
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut
However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1
* note prior CDK not required
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Reposted by Ahmed Elkhanany
10 year follow up on OlympiA shows persistent benefit in iDFS, OS. #SABCS24 @oncoalert.bsky.social
December 11, 2024 at 5:30 PM
10 year follow up on OlympiA shows persistent benefit in iDFS, OS. #SABCS24 @oncoalert.bsky.social
Dr Luca Malorni presented very thought provoking TOUCH study in ER/HER2+ with neoadj HP/Taxol vs HP/Palbo Letrozole. pCR 32.9 vs 33.3%. In high RBsig, Palbo/AI did better!
Another no-chemo Rx next to KRISTINE. Qs: PAM50 role? CDK/ET replacing Taxol in NACT? What about CDK in ABC?
#SABCS24
#bcsm
Another no-chemo Rx next to KRISTINE. Qs: PAM50 role? CDK/ET replacing Taxol in NACT? What about CDK in ABC?
#SABCS24
#bcsm
December 11, 2024 at 6:41 PM
Great data on PADMA presented by Dr. Loibl in 1st L HR+ MBC btw Chemo + maintenance ET vs. Palbo + ET. Palbo more than doubled time to treatment failure (6 vs 17 months)
Same data in RIGHT CHOICE with PFS 21.8 vs 12.8 months in RiboET vs CT. No more chemo 1st L!
#SABCS24
#bcsm
@sabcs.bsky.social
Same data in RIGHT CHOICE with PFS 21.8 vs 12.8 months in RiboET vs CT. No more chemo 1st L!
#SABCS24
#bcsm
@sabcs.bsky.social
December 11, 2024 at 12:37 AM
Great data on PADMA presented by Dr. Loibl in 1st L HR+ MBC btw Chemo + maintenance ET vs. Palbo + ET. Palbo more than doubled time to treatment failure (6 vs 17 months)
Same data in RIGHT CHOICE with PFS 21.8 vs 12.8 months in RiboET vs CT. No more chemo 1st L!
#SABCS24
#bcsm
@sabcs.bsky.social
Same data in RIGHT CHOICE with PFS 21.8 vs 12.8 months in RiboET vs CT. No more chemo 1st L!
#SABCS24
#bcsm
@sabcs.bsky.social
Great stepwise approach. Also good reminder that topical estrogen therapy did NOT demonstrate increased risk of recurrences per multiple trials incl Cold et al JNCI 2022 and metaanalysis by Beste et al AJOG 2024
#sabcs24
#bcsm
#sabcs24
#bcsm
#SABCS24 #bcsm #OncSky
We need to ask all patients on endocrine therapy for #breastcancer about vaginal dryness & sexual dysfunction. Here’s a useful stepwise approach to managing these issues from
@JenniShengMD. #MedSky
@oncoalert.bsky.social
We need to ask all patients on endocrine therapy for #breastcancer about vaginal dryness & sexual dysfunction. Here’s a useful stepwise approach to managing these issues from
@JenniShengMD. #MedSky
@oncoalert.bsky.social
December 11, 2024 at 12:13 AM
An important money slide in discordance of variants between cfDNA and tumor testing. Panel by stellar Dr. Ellen Landsberger who shared some tough Qs on utility of cfDNA from Pt advocates POV.
Take home: Breast CA has high rate of novel variants on cfDNA not on tumor
#SABCS24
@sabcs.bsky.social
Take home: Breast CA has high rate of novel variants on cfDNA not on tumor
#SABCS24
@sabcs.bsky.social
December 10, 2024 at 11:43 PM
An important money slide in discordance of variants between cfDNA and tumor testing. Panel by stellar Dr. Ellen Landsberger who shared some tough Qs on utility of cfDNA from Pt advocates POV.
Take home: Breast CA has high rate of novel variants on cfDNA not on tumor
#SABCS24
@sabcs.bsky.social
Take home: Breast CA has high rate of novel variants on cfDNA not on tumor
#SABCS24
@sabcs.bsky.social
OFS for fertility perservation is severely underutilized. AYA discussion with young Pts is paramount & need routine workflow
On separate note, there remains a gap in using OFS for HR+ HER2+. Data are a little different (T/OFS better than E/OFS) but they were small percent of population.
#SABCS24
On separate note, there remains a gap in using OFS for HR+ HER2+. Data are a little different (T/OFS better than E/OFS) but they were small percent of population.
#SABCS24
December 10, 2024 at 11:27 PM
OFS for fertility perservation is severely underutilized. AYA discussion with young Pts is paramount & need routine workflow
On separate note, there remains a gap in using OFS for HR+ HER2+. Data are a little different (T/OFS better than E/OFS) but they were small percent of population.
#SABCS24
On separate note, there remains a gap in using OFS for HR+ HER2+. Data are a little different (T/OFS better than E/OFS) but they were small percent of population.
#SABCS24
Everyday there is at least one TBCRC presentation in #SABCS24. Such a wonderful consortium and amazing dedicated investigators. Since inception, 64 breast trials (and counting). @hoperugo.bsky.social @ptarantinomd.bsky.social @meghanflanigan.bsky.social #bcsm
December 10, 2024 at 9:51 PM
Everyday there is at least one TBCRC presentation in #SABCS24. Such a wonderful consortium and amazing dedicated investigators. Since inception, 64 breast trials (and counting). @hoperugo.bsky.social @ptarantinomd.bsky.social @meghanflanigan.bsky.social #bcsm
I have to salute #SABCS24 on the amazing tech platform site and app at events.hubilo.com/sabcs2024/home and at play.google.com/store/apps/d.... The live streaming, almost instant replayability of sessions, note-taking. Please make best use of the site/app (especially for live viewing)
December 10, 2024 at 9:42 PM
I have to salute #SABCS24 on the amazing tech platform site and app at events.hubilo.com/sabcs2024/home and at play.google.com/store/apps/d.... The live streaming, almost instant replayability of sessions, note-taking. Please make best use of the site/app (especially for live viewing)
This was a wonderful session. Highly recommend to rewatch for those who have tough time where to start applying for funds. Foundational, NIH, and industry venues. Also internal CCSG funds and SPORE CDA. @stolaney1.bsky.social @Minetta Liu, @Larissa Korde @Brenda Ernst #SABCS24 #bcsm
December 10, 2024 at 9:18 PM
This was a wonderful session. Highly recommend to rewatch for those who have tough time where to start applying for funds. Foundational, NIH, and industry venues. Also internal CCSG funds and SPORE CDA. @stolaney1.bsky.social @Minetta Liu, @Larissa Korde @Brenda Ernst #SABCS24 #bcsm
Impressive work by SWOG and RxPONDER team including Kevin Kalinsky and my dear friend Yara Abdou. Both IDFS & DRFS worse for black Pts vs. whites (91.6% vs 87.1% & 95.8% vs 91.0%). Chemotherapy efficacy is same. BMI played role in outcome @oncoalert.bsky.social #bcsm #oncosky. tinyurl.com/eptu2pap
Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial
AbstractBackground. The phase III RxPONDER trial has impacted treatment for node-positive(1-3), hormone receptor-positive, HER2-negative breast cancer with
academic.oup.com
December 9, 2024 at 2:44 PM
Impressive work by SWOG and RxPONDER team including Kevin Kalinsky and my dear friend Yara Abdou. Both IDFS & DRFS worse for black Pts vs. whites (91.6% vs 87.1% & 95.8% vs 91.0%). Chemotherapy efficacy is same. BMI played role in outcome @oncoalert.bsky.social #bcsm #oncosky. tinyurl.com/eptu2pap
Reposted by Ahmed Elkhanany
Genome-wide association analyses in Nature Genetics provide insights into the molecular etiology of dilated cardiomyopathy, which may inform the design of genetic testing strategies and may facilitate the development of targeted therapeutics. https://go.nature.com/4fIkNmh 🧪
November 27, 2024 at 7:08 PM
Genome-wide association analyses in Nature Genetics provide insights into the molecular etiology of dilated cardiomyopathy, which may inform the design of genetic testing strategies and may facilitate the development of targeted therapeutics. https://go.nature.com/4fIkNmh 🧪
Reposted by Ahmed Elkhanany
Come join me Thursday morning Dec 12 as I discuss these wonderful 4 poster highlights #sabcs24 #survonc #bcsm @sabcs.bsky.social
November 30, 2024 at 9:36 PM
Come join me Thursday morning Dec 12 as I discuss these wonderful 4 poster highlights #sabcs24 #survonc #bcsm @sabcs.bsky.social
Reposted by Ahmed Elkhanany
My feed is filled with misinformation re: aid in dying. A fewcpoints to clear up. #medsky #oncsky
1. Where it's legal, a physician cannot assist. That is, the person with a terminal dx opting to die must administer meds to self- no help. Hence, it isn't physician assisted suicide 1/5
1. Where it's legal, a physician cannot assist. That is, the person with a terminal dx opting to die must administer meds to self- no help. Hence, it isn't physician assisted suicide 1/5
December 1, 2024 at 10:55 AM